About: Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: $4.76 (+3.03%)
AQST NASDAQ Aquestive Therapeutics Inc
Aquestive Therapeutics Inc share price
AQST price activity
Último preço
$ 4,760
Variação (24h)
0,14 USD (3,03%)
Volume
2.31M
Volume (média 4 sem.)
-
Abertura
$ 4,62
Variação do dia
$ 4,55 - $ 4,85
Fechamento anterior
$ 4,62
Último negócio
08 Oct, 8:15 pm GMT+0
Atrasado
08 Oct, 8:15 pm GMT+0
AQST price performance
Atrasado
08 Oct, 8:15 pm GMT+0
quote.marketSignals